Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · October 24, 2023

ESMO 2023: Neoadjuvant Nivolumab + Chemo Aids Survival With Resectable Non-Small Cell Lung Cancer

42 percent lower risk for event-free recurrence seen for neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab

PracticeUpdate Editorial Team


Further Reading